Cargando…

A Poliovirus Receptor (CD155)-Related Risk Signature Predicts the Prognosis of Bladder Cancer

BACKGROUND: Bladder cancer is an aggressive and heterogeneous disease associated with high morbidity and mortality. And poliovirus receptor (PVR or CD155) played crucial roles in tumor immune microenvironment and cancer development. However, their association remains obscure. METHODS: A total of 797...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Cong, Ye, Wenrui, Hu, Jiao, Othmane, Belaydi, Li, Huihuang, Chen, Jinbo, Zu, Xiongbing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8210672/
https://www.ncbi.nlm.nih.gov/pubmed/34150627
http://dx.doi.org/10.3389/fonc.2021.660273
_version_ 1783709357283737600
author Luo, Cong
Ye, Wenrui
Hu, Jiao
Othmane, Belaydi
Li, Huihuang
Chen, Jinbo
Zu, Xiongbing
author_facet Luo, Cong
Ye, Wenrui
Hu, Jiao
Othmane, Belaydi
Li, Huihuang
Chen, Jinbo
Zu, Xiongbing
author_sort Luo, Cong
collection PubMed
description BACKGROUND: Bladder cancer is an aggressive and heterogeneous disease associated with high morbidity and mortality. And poliovirus receptor (PVR or CD155) played crucial roles in tumor immune microenvironment and cancer development. However, their association remains obscure. METHODS: A total of 797 patients from TCGA and GEO databases were employed in our study, in which 285 cases were set as the training cohort and 512 were defined as the validation cohort. Our own Xiangya cohort with 57 samples was also used for the validation. Survival differences were evaluated by Kaplan-Meier analysis between groups. The immune infiltration was evaluated by ESTIMATE, TIMER, and CIBERSORT algorithms. The risk signature was constructed by LASSO Cox regression analysis. And a nomogram model was generated subsequent to the multivariate Cox proportional hazards analysis to predict 3- and 5-year survival of patients with bladder cancer. RESULTS: PVR was overexpressed across various cancers including bladder cancer and related to poorer overall survival in bladder urothelial carcinoma (BLCA). Samples with higher World Health Organization (WHO) grade or higher tumor stage tended to express higher level of PVR. And PVR-related genes were involved in several immune processes and oncological pathways. When the patients were divided into low- and high-risk groups based on their risk scores, we found that patients in the high-risk group had shorter overall survival time. Besides, samples with high risk were consistently correlated with tumor hallmarks and higher abundance of immune infiltration. Additionally, chemotherapy showed potent efficacy in high-risk group. Moreover, a nomogram including clinicopathologic features and the established risk signature could predict 3- and 5-year survival in patients with bladder cancer. CONCLUSION: Our study revealed that PVR was overexpressed and related to poor prognosis in bladder cancer. A risk signature and nomogram model based on PVR-related genes could predict the prognosis and therapeutic efficacy and were also associated with the immune infiltration in bladder cancer.
format Online
Article
Text
id pubmed-8210672
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-82106722021-06-18 A Poliovirus Receptor (CD155)-Related Risk Signature Predicts the Prognosis of Bladder Cancer Luo, Cong Ye, Wenrui Hu, Jiao Othmane, Belaydi Li, Huihuang Chen, Jinbo Zu, Xiongbing Front Oncol Oncology BACKGROUND: Bladder cancer is an aggressive and heterogeneous disease associated with high morbidity and mortality. And poliovirus receptor (PVR or CD155) played crucial roles in tumor immune microenvironment and cancer development. However, their association remains obscure. METHODS: A total of 797 patients from TCGA and GEO databases were employed in our study, in which 285 cases were set as the training cohort and 512 were defined as the validation cohort. Our own Xiangya cohort with 57 samples was also used for the validation. Survival differences were evaluated by Kaplan-Meier analysis between groups. The immune infiltration was evaluated by ESTIMATE, TIMER, and CIBERSORT algorithms. The risk signature was constructed by LASSO Cox regression analysis. And a nomogram model was generated subsequent to the multivariate Cox proportional hazards analysis to predict 3- and 5-year survival of patients with bladder cancer. RESULTS: PVR was overexpressed across various cancers including bladder cancer and related to poorer overall survival in bladder urothelial carcinoma (BLCA). Samples with higher World Health Organization (WHO) grade or higher tumor stage tended to express higher level of PVR. And PVR-related genes were involved in several immune processes and oncological pathways. When the patients were divided into low- and high-risk groups based on their risk scores, we found that patients in the high-risk group had shorter overall survival time. Besides, samples with high risk were consistently correlated with tumor hallmarks and higher abundance of immune infiltration. Additionally, chemotherapy showed potent efficacy in high-risk group. Moreover, a nomogram including clinicopathologic features and the established risk signature could predict 3- and 5-year survival in patients with bladder cancer. CONCLUSION: Our study revealed that PVR was overexpressed and related to poor prognosis in bladder cancer. A risk signature and nomogram model based on PVR-related genes could predict the prognosis and therapeutic efficacy and were also associated with the immune infiltration in bladder cancer. Frontiers Media S.A. 2021-06-03 /pmc/articles/PMC8210672/ /pubmed/34150627 http://dx.doi.org/10.3389/fonc.2021.660273 Text en Copyright © 2021 Luo, Ye, Hu, Othmane, Li, Chen and Zu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Luo, Cong
Ye, Wenrui
Hu, Jiao
Othmane, Belaydi
Li, Huihuang
Chen, Jinbo
Zu, Xiongbing
A Poliovirus Receptor (CD155)-Related Risk Signature Predicts the Prognosis of Bladder Cancer
title A Poliovirus Receptor (CD155)-Related Risk Signature Predicts the Prognosis of Bladder Cancer
title_full A Poliovirus Receptor (CD155)-Related Risk Signature Predicts the Prognosis of Bladder Cancer
title_fullStr A Poliovirus Receptor (CD155)-Related Risk Signature Predicts the Prognosis of Bladder Cancer
title_full_unstemmed A Poliovirus Receptor (CD155)-Related Risk Signature Predicts the Prognosis of Bladder Cancer
title_short A Poliovirus Receptor (CD155)-Related Risk Signature Predicts the Prognosis of Bladder Cancer
title_sort poliovirus receptor (cd155)-related risk signature predicts the prognosis of bladder cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8210672/
https://www.ncbi.nlm.nih.gov/pubmed/34150627
http://dx.doi.org/10.3389/fonc.2021.660273
work_keys_str_mv AT luocong apoliovirusreceptorcd155relatedrisksignaturepredictstheprognosisofbladdercancer
AT yewenrui apoliovirusreceptorcd155relatedrisksignaturepredictstheprognosisofbladdercancer
AT hujiao apoliovirusreceptorcd155relatedrisksignaturepredictstheprognosisofbladdercancer
AT othmanebelaydi apoliovirusreceptorcd155relatedrisksignaturepredictstheprognosisofbladdercancer
AT lihuihuang apoliovirusreceptorcd155relatedrisksignaturepredictstheprognosisofbladdercancer
AT chenjinbo apoliovirusreceptorcd155relatedrisksignaturepredictstheprognosisofbladdercancer
AT zuxiongbing apoliovirusreceptorcd155relatedrisksignaturepredictstheprognosisofbladdercancer
AT luocong poliovirusreceptorcd155relatedrisksignaturepredictstheprognosisofbladdercancer
AT yewenrui poliovirusreceptorcd155relatedrisksignaturepredictstheprognosisofbladdercancer
AT hujiao poliovirusreceptorcd155relatedrisksignaturepredictstheprognosisofbladdercancer
AT othmanebelaydi poliovirusreceptorcd155relatedrisksignaturepredictstheprognosisofbladdercancer
AT lihuihuang poliovirusreceptorcd155relatedrisksignaturepredictstheprognosisofbladdercancer
AT chenjinbo poliovirusreceptorcd155relatedrisksignaturepredictstheprognosisofbladdercancer
AT zuxiongbing poliovirusreceptorcd155relatedrisksignaturepredictstheprognosisofbladdercancer